Transcode Therapeutics, Inc.
RNAZ- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001829635
No open-market purchases or sales by Transcode Therapeutics, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $208.1K in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding Transcode Therapeutics, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 10 | 5 | −5 |
| Shares | 325.3K | 9.91K | −315.4K (−97.0%) |
| Value | $185.8K | $33.4K | −$152.4K (−82.0%) |
New holders (1)
Institutions that held Transcode Therapeutics, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| UBS Group AG | 8,676 | $29.2K | 0.00% |
Sold out (6)
Institutions that held Transcode Therapeutics, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Geode Capital Management, LLC | 121,768 | $69.5K |
| Private Capital Management LLC | 80,675 | $46.1K |
| Sheets Smith Wealth Management | 50,138 | $28.6K |
| Jane Street Group, LLC | 39,706 | $22.7K |
| Captrust Financial Advisors | 16,250 | $9.28K |
| FMR LLC | 175 | $100 |